Diffusion of E and Z urocanic amphiphiles through skin and their insertion in a membrane model.

The incorporation of synthetic urocanic amphiphiles into a membrane model is described. A monomolecular film of dipalmitoyl phosphatidylcholine (DPPC) and cholesterol was formed at the air-water interface and used as a model. In parallel, diffusion of these derivatives through the skin was studied using rat skin on flow-through diffusion cells. The flux and the cumulative amount were determined. Although the structure and the composition of the DPPC/cholesterol monolayer differed greatly from multilayers of epidermal lipids, the results obtained in the incorporation and diffusion studies were similar. The structure of the urocanic amphiphiles was very close, but the membranes led to the following flux or insertion classification: Ester E > Ester Z >> Amide E. From the results obtained and for simplicity, the technique of Langmuir monolayers seems to be highly suited to the primary screening of amphiphilic compounds.

Comparison of the DNA damage photoinduced by fenofibrate and ketoprofen, two phototoxic drugs of parent structure.

Fenofibrate and ketoprofen (KP) are two drugs of similar structure derived from that of benzophenone. Both are photoallergic and promote cross reactions in patients. However, the cutaneous photosensitizing properties of KP also include phototoxic effects and are more frequently mentioned. To account for this difference in their in vivo properties, their in vitro photosensitizing properties on DNA were compared. First, it was shown that under irradiation at 313 nm, fenofibric acid (FB), the main metabolite of fenofibrate, photosensitized DNA cleavage by a radical mechanism similar to that proposed for KP but with a 50 times lower efficiency. Furthermore, FB did not photosensitize the formation of pyrimidine dimers into DNA in contrast to KP, which did promote this type of DNA damage. Their difference in efficiency as DNA breakers was compared to their relative photochemical reactivity and the quantum yield of FB photolysis was found to be eightfold lower than that of KP. The reactivity of these drugs cannot explain alone the difference in their photosensitizing properties. Other factors such as the magnitude of the ionic character of the photodecarboxylation pathway of these benzophenone-like drugs are considered in the discussion.

Structural determination of a glucuronide conjugate of flucytosine in humans.

The structure of a glucuronide metabolite of flucytosine (FC; 5-fluorocytosine), found in the urine of all patients treated with this antifungal drug, was determined. This compound is the O2-beta-glucuronide of FC. Its structure was established after isolation from urine and by comparing its spectroscopic characteristics with those of three FC glucuronides previously synthesized. This study is the first report of the identification of a glucuronide of a fluoropyrimidine drug in humans.

Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.

Phosphorus-31 nuclear magnetic resonance spectroscopy was used to analyze urine samples obtained from patients treated with ifosfamide (IF). This technique allows the individual assay of all phosphorated metabolites of IF in a single analysis without the need for prior extraction. In addition to the classic IF metabolites 2-dechloroethylifosfamide (2DEC1IF), 3-dechloroethylifosfamide (3DEC1IF), carboxyifosfamide (CARBOXYIF), and isophosphoramide mustard (IPM), several signals corresponding to unknown phosphorated compounds were observed. Four of them were identified: one is alcoifosfamide (ALCOIF), two come from the degradation of 2,3-didechloroethylifosfamide (2,3-DEC1IF), and one results from the decomposition of 2DEC1IF. The total cumulative drug excretion as measured over 24 h in nine patients was 51% of the injected IF dose; 18% of the dose was recovered as unchanged IF. The major urinary metabolites were the dechloroethylated compounds, with 3DEC1IF excretion (11% of the injected dose) always being superior to 2DEC1IF elimination (4% of the injected dose). Degradation compounds of 2DEC1IF and 2,3DEC1IF represented 0.4% of the injected dose. The metabolites of the dechloroethylation pathway always predominated over those of the activation pathway (CARBOXYIF, ALCOIF, and IPM, representing 3%, 0.8%, and 0.2% of the injected dose, respectively). In all, 14% of the injected dose was excreted as unknown phosphorated compounds. The interpatient variation in levels of IF metabolites was obvious and involved all of the metabolites. Renal excretion was not complete at 24 h, since 11% of the injected dose was recovered in the 24- to 48-h urine samples.